

Honolulu, Hawaii

APR 04 , 2024

RE: H.R. No. 166
H.D. 1

Honorable Scott K. Saiki
Speaker, House of Representatives
Thirty-Second State Legislature
Regular Session of 2024
State of Hawaii

Sir:

Your Committee on Finance, to which was referred H.R. No. 166, H.D. 1, entitled:

"HOUSE RESOLUTION URGING THE GOVERNOR, DEPARTMENT OF HUMAN SERVICES, AND DEPARTMENT OF HEALTH TO EXPLORE AVENUES TO ENSURE CONTINUED ACCESS TO AFFORDABLE MEDICATIONS FOR THE STATE'S UNDERSERVED POPULATIONS UNDER THE 340B DRUG PRICING PROGRAM AND URGING HAWAII'S CONGRESSIONAL DELEGATION AND RELEVANT FEDERAL AGENCIES TO MONITOR PHARMACEUTICAL COMPANIES AND TAKE APPROPRIATE ACTIONS TO PROTECT THE INTEGRITY OF THE 340B DRUG PRICING PROGRAM,"

begs leave to report as follows:

The purpose of this measure is to urge the Governor, Department of Human Services, and Department of Health to explore avenues to ensure continued access to affordable medications for the State's underserved populations under the 340B drug pricing program and urging Hawaii's congressional delegation and relevant federal agencies to monitor pharmaceutical companies and take appropriate actions to protect the integrity of the 340B drug pricing program.

As affirmed by the record of votes of the members of your Committee on Finance that is attached to this report, your Committee concurs with the intent and purpose of H.R. No. 166, H.D. 1, and recommends its adoption.

HR166 HD1 HSCR FIN



Respectfully submitted on
behalf of the members of the
Committee on Finance;

Kyle T. Yamashita for

KYLE T. YAMASHITA, Chair



